Results 51 to 60 of about 13,727 (197)

Melhora no Consumo Máximo de Oxigênio e na Ventilação após Tratamento com Sacubitril-Valsartana [PDF]

Arquivos Brasileiros de Cardiologia, 2020
Resumo Fundamento O tratamento com sacubitril-valsartana teve seu benefício prognóstico confirmado no ensaio PARADIGM-HF. No entanto, dados sobre alterações no teste de esforço cardiopulmonar (TECP) com o uso de sacubitril-valsartana são escassos ...
António Valentim Gonçalves, Tiago Pereira-da-Silva, Ana Galrinho, Pedro Rio, Rui Soares, Joana Feliciano, Rita Ilhão Moreira, Sofia Silva, Sandra Alves, Eunice Capilé, Rui Cruz Ferreira   +10 more
doaj   +3 more sources

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Has the 'epidemic’ of heart failure been replaced by a tsunami of co-morbidities? [PDF]

, 2016
No abstract ...
Bhatt, Callender, Cohen-Solal, Cowie, Ezekowitz, Fitchett, Jhund, Jhund, Komajda, Kotecha, Parén, Redfield, Schmidt, Scirica, Tavazzi, Urso, Vardas, Wasywich   +17 more
core   +1 more source

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials

Cardiovascular Diabetology, 2022
Background Compared with enalapril, sacubitril/valsartan lowered HbA1c and reduced new insulin therapy in patients with heart failure with reduced ejection fraction (HFrEF) and diabetes in the PARADIGM-HF trial.
Magnus O. Wijkman, Brian Claggett, Muthiah Vaduganathan, Jonathan W. Cunningham, Rasmus Rørth, Alice Jackson, Milton Packer, Michael Zile, Jean Rouleau, Karl Swedberg, Martin Lefkowitz, Sanjiv J. Shah, Marc A. Pfeffer, John J. V. McMurray, Scott D. Solomon   +14 more
doaj   +1 more source

Machine learning‐based prediction of elevated N terminal pro brain natriuretic peptide among US general population

ESC Heart Failure, Volume 12, Issue 2, Page 859-868, April 2025.
Abstract Aims Natriuretic peptide‐based pre‐heart failure screening has been proposed in recent guidelines. However, an effective strategy to identify screening targets from the general population, more than half of which are at risk for heart failure or pre‐heart failure, has not been well established.
Yuichiro Mori, Shingo Fukuma, Kyohei Yamaji, Atsushi Mizuno, Naoki Kondo, Kosuke Inoue   +5 more
wiley   +1 more source

Review Article : Sacubitril/valsartan use for the hospitalist [PDF]

, 2017
The mainstays of therapy for heart failure with reduced ejection fraction (HFrEF) have traditionally been angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), beta-blockers, aldosterone receptor antagonists, and ...
Hart, James, Littrell, Rachel, Padkins, Mitchell   +2 more
core   +1 more source

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction

Cardiac Failure Review, 2021
Sacubitril with valsartan (sacubitril/valsartan) is a relatively novel compound that has become a milestone in the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) in the last decade.
Mauro Gori, James L Januzzi, Emilia D’Elia, Ferdinando L Lorini, Michele Senni   +4 more
doaj   +1 more source

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm [PDF]

, 2016
Many conditions culminate in heart failure (HF), a multi-organ systemic syndrome with an intrinsically poor prognosis. Pharmacotherapeutic agents that correct neurohormonal dysregulation and haemodynamic instability have occupied the forefront of ...
Abozguia, AIRE Study Group, Alexander, Alexander, Alexander, Alexander, Ashrafian, Bailey, Bailey, Basu, Beadle, Braunwald, Brown, Burgoyne, Chaitman, Chatterjee, Chung, CIBIS-II Study Group, Cleland, Clerc, Cohn, Cohn, Cohn, CONSENSUS Trial Study Group, Conway, Cook, Dai, Digitalis Investigation Group, Doenst, Dzau, Dzau, Faris, Flather, Follath, Foster, Fox, Fox, Fragasso, Furberg, Gheorghiade, Gladwin, Goffart, Granger, Greenberg, Guazzi, Guazzi, Heymans, Hobbs, Holubarsch, Horowitz, Horowitz, Kantor, Kapil, Kato, Kennedy, Kennedy, Kostis, Larsen, Lee, Lopaschuk, Luiken, Lundberg, Maher, Maier, Mancini, Mann, Mann, Massie, Mccormack, Mcdowell, Mcmurray, Mcmurray, Merit-Hf Study Group, Munzel, Munzel, Neglia, Neubauer, Ormerod, Packer, Packer, Paul, Pawson, Pfeffer, Pfeffer, Pitt, Pitt, Rathore, Rauchhaus, Redfield, Rona, Sack, Sarraf, Schmidt-Schweda, Schrauwen, Schwarz, Shah, Shah, Siddiqi, Singh, SOLVD Investigators, Stanley, Swedberg, Szwed, Taylor, Teerlink, Tilemann, Torre-Amione, Totzeck, Turcani, Unger, Van Der Vusse, Van Faassen, Vardeny, Webb, Yin, Yusuf, Zamani, Zannad, Zannad, Zhang   +119 more
core   +1 more source

The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review

Journal of Cardiovascular Pharmacology and Therapeutics, 2022
Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the treatment of HF.
Rui Zhang MD, PhD, Xiaotong Sun PhD, Ya Li MD, PhD, Wenzheng He MM, Hongguang Zhu MD, PhD, Baoshan Liu MD, PhD, Aiyuan Zhang MD, PhD   +6 more
doaj   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source